Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In addition, we explore the clinical data of DLC1 and the mechanisms that natural products upregulate the DLC1 expression to inhibit cancer.
|
31773748 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Deleted in Liver Cancer 1 (DLC1) is a tumor suppressor gene deleted in many cancers, including angiosarcoma, an aggressive malignancy of endothelial cell derivation.
|
31409902 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
However, DLC1 is not known to be deleted in angiosarcoma, an aggressive malignancy of endothelial cell derivation.
|
29202196 |
2018 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This study was designed to investigate the biological role of DLC1 in resveratrol induced cancer cellular senescence.
|
29964052 |
2018 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A tumor suppressor Deleted in Liver Cancer 1 (DLC1) has been reported to be down-regulated or even silenced in several kinds of cancer including breast cancer.
|
27830358 |
2017 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DLC1 is a critical AKT target in DLC1-positive cancer because AKT inhibition has potent antitumor activity in the DLC1-positive transgenic cancer model and in a DLC1-positive cancer cell line but not in an isogenic DLC1-negative cell line.
|
29114068 |
2017 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
DLC1 expression was higher in TCGA LAD patients who remained cancer-free, while low DLC1 had a poorer prognosis than low DLC2 or low DLC3 in a more completely annotated database.
|
27174913 |
2016 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Compared with non-tumorigenic cells, H2O2 increased expression of DLC1 and reduced activity of RhoA in cancer cells.
|
25743845 |
2015 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Aberrant DLC-1 expression may play an important role in cancer genesis and metastasis.
|
26514520 |
2015 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The biological function of tumor suppressor deleted in liver cancer 1 (DLC1) has been investigated in several types of human cancer, but its role in gallbladder cancer (GBC) is yet to be determined.
|
24329682 |
2014 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These data suggest that DLC1 might act as a CHD-associated gene in addition to its role as a tumor suppressor in cancer.
|
24587289 |
2014 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Inactivation of DLC1 results in hyper-activated Rho/ROCK signaling and is implicated in actin cytoskeleton reorganization to promote cancer metastasis.
|
23826380 |
2013 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This study explored the potential role of deleted in liver cancer-1 (DLC-1) as a prognostic indicator of cancer metastasis and survival in urothelial carcinoma (UC).
|
23510351 |
2013 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DLC1 encodes a RhoA GTPase-activating protein and tumor suppressor lost in cancer by genomic deletion or epigenetic silencing and loss of DLC1 gene transcription.
|
24082123 |
2013 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Inactivation of the Dlc1 gene cooperates with downregulation of p15INK4b and p16Ink4a, leading to neoplastic transformation and poor prognosis in human cancer.
|
23010077 |
2012 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Deleted in liver cancer 1 (DLC1), a tumor suppressor gene frequently inactivated in non-small cell lung cancer (NSCLC) and other malignancies, encodes a multidomain protein with a RhoGTPase-activating (RhoGAP) domain and a StAR-related lipid transfer (START) domain.
|
22693251 |
2012 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our study therefore links dynamic regulation of tensin family members by EGF to Rho-GAP through DLC1 and suggests that the tensin-DLC1-RhoA signaling axis plays an important role in tumorigenesis and cancer metastasis, and may be explored for cancer intervention.
|
22307599 |
2012 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
DLC-1 expression levels in breast cancer assessed by qRT- PCR are negatively associated with malignancy.
|
22799310 |
2012 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
The transcription of DLC1 (deleted in liver cancer), a tumor suppressor gene, is frequently silenced in various types of human cancer.
|
21455586 |
2011 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Deleted in liver cancer-1(DLC-1) gene expression is frequently down-regulated or deleted in many types of human cancer.
|
20882354 |
2011 |
Malignant Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
However, differential expression of the four DLC1 isoforms is found in tumor cell lines: Isoform 1 (longest) and 3 (short thus probably nonfunctional) share a promoter and are silenced in almost all cancer and immortalized cell lines, whereas isoform 2 and 4 utilize different promoters and are frequently downregulated.
|
21217778 |
2011 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These results provide the first evidence for the antiproliferative effect of DLC1 in a hematological cancer and implicate RhoA pathway in suppression of MM migration and invasion.
|
18923442 |
2009 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The canine DLC1 is constructed highly similarly to the human gene, which has been shown to be an important tumor suppressor in many forms of cancer.
|
19912643 |
2009 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Deleted in liver cancer 1 (DLC1), a member of RhoGTPase activating protein (GAP) family, is known to have suppressive activities in tumorigenicity and cancer metastasis.
|
18648664 |
2008 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DLC1: a significant GAP in the cancer genome.
|
18593873 |
2008 |